Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.

GREY:ADXS - Post by User

Ayala Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(0)
•••

Post by AllianceSeanon Jun 11, 2021 3:00pm

266 Views

Post# 33373548

Advaxis Wants Your Vote

Hello Everyone:

This is Sean-a proxy voting specialist at Alliance Advisors. The Annual Meeting of Shareholders for Advaxis is closely approaching on June 17th, 2021, and the company needs your votes. We want to make ourselves available on the forums to answer any annual meeting questions you have.

And when you are ready to vote your shares, call us at our toll-free number at 855-928-4484 Monday through Friday 9:00am to 10:00pm EST or Email us: proxyvoting@allianceadvisors.com. My fellow proxy voting specialists ready to assist you. Your vote is important, and your time is appreciated.

<< Previous

Bullboard Posts

Next >>

The 5-Minute Investor Podcast, Ep. 37: Cancer-fighting stocks